Top

Published in:

01-03-2013 | Review Article

Systemic Therapy in Head and Neck Cancer: Changing Paradigm

Authors: Samit Purohit, Rohan Bhise, D. Lokanatha, K. Govindbabu

Published in: Indian Journal of Surgical Oncology | Issue 1/2013

Abstract

Head and neck cancers comprise a heterogenous group of cancers that require a multidisciplinary approach. Last few decades have seen an increasing role of chemotherapy with intent of treatment shifting from palliation to cure. We performed a thorough search online and offline for all relevant articles of chemotherapy in head and neck cancer. Cancers of nasopharynx and salivary glands were excluded.

Posner MR (2010) Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice. ASCO. 205–209

Dayyani F, Etzel CJ, Liu M, Ho C-H, Lippman SM, Tsao AS (2010) Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2:15PubMedCrossRef

Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077PubMedCrossRef

Cambell JB, Dorman EB, McCormick M et al (1987) A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-flurouracil in end stage head and neck cancer. Acta Otolaryngol 103:519–528

Morton RP, Rugman F, Dorman EB et al (1992) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 15:283–289

Eisenberger M, Hornedo J, Silva H et al (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous cell carcinoma of head and neck. J Clin Oncol 4:1506–1509PubMed

Eisenberger M, Krasnow S, Ellenberg S et al (1989) A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 7:1341–1345PubMed

Schornagel JH, Verweij J, de Mulder PH et al (1995) Randomised phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of head and neck: a European Organisation for research and treatment of cancer head and neck cancer cooperative group study. J Clin Oncol 13:1649–1655PubMed

Tapazoglou E, Kish J, Ensley J et al (1986) The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57:1105–1109PubMedCrossRef

10.

Buesa JM, Fernandez R, Esteban E et al (1991) Phase II trial of ifosfamide in recurrent and metastatic head and cancer. Ann Oncol 2:151–152PubMedCrossRef

11.

Cervellino JC, Araujo CE, Pirisi C et al (1991) Ifosfamide and mesna in treatment of advanced squamous cell carcinoma of head and neck. Oncology 48:89–92PubMedCrossRef

12.

Couteau C, Chouaki N, Leyvraz S et al (1999) A phase II study of docetaxel in metastatic squamous cell carcinoma of head and neck. Br J Cancer 81:457–462PubMedCrossRef

13.

Dreyfuss AI, Clark JR, Norris CM et al (1996) Docetaxel: an active drug for squamous cell carcinoma of head and neck. J Clin Oncol 14:1672–1678PubMed

14.

Gebbia V, Testa A, Cannata G et al (1996) Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 32A:901–902PubMedCrossRef

15.

Smith RE, Thornton DE, Allen J (1995) A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22:41–46PubMed

16.

Jacob’s C, Meyers F, Hendrickson C et al (1983) A randomized phase III study of cisplatin with or without methotrexate for recurrent and squamous cell carcinoma of head and neck: a North California Oncology group study. Cancer 52:1563–1569CrossRef

17.

Drelichman A, Cummings G, AL-Sarraf M et al (1983) A randomized trial of the combination of cisplatin, oncovin and bleomycin (COB) versus methotreaxte in patients with advanced squamous cell carcinoma of the head and neck. Cancer 52:399–403PubMedCrossRef

18.

Williams S, Velex-Garcia E, Essessee I et al (1986) Chemotherapy for head and neck cancer: comparison of cisplatin, vinblastin, bleomycin versus methotrexate. Cancer 57:18–23PubMedCrossRef

19.

Jacobs C, Lyman G, Velez-garcia E et al (1992) A phase III randomized study comparing cisplatin and flurouracil as single agents and in combination for advanced squamous cell carcinoma of head and neck. J Clin Oncol 10:257–263PubMed

20.

Forastiere A, Metch B, Schuller D et al (1992) Randomised comparison of cisplatin plus 5 flurouracil and carboplatin plus flurouracil versus methotrexate in advanced squamous-cell carcinoma of head and neck: a south west oncology group study. J Clin Oncol 10:1245–1251PubMed

21.

Clavel M, Vermoken JB, Cognetti F et al (1994) Randomised comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5 Fu (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526PubMed

22.

Browman GP, Cronin L (1994) Standard chemotherapy in squamous cell head and neck cancer: what have we learned from randomized trials. Semin Oncol 21:311–319PubMed

23.

Murphy B, Li Y, Cella D et al (2001) Phase III study comparing cisplatin (C) & 5 flurouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head and neck cancer. Proc Annu Meet Am Soc Clin Oncol 20:A894

24.

Schoffski P, Catimel G, Planting AST et al (1999) Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10:119–122PubMedCrossRef

25.

Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85:95–111PubMedCrossRef

26.

Randolf VL, Vellejo A, Spiro RH et al (1978) Combination therapy for advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 41:460–467CrossRef

27.

Hong WK, Shapshay SM, Bhutani R et al (1979) Induction chemotherapy in advanced squamous head and neck cancer with high dose cisplatinum and bleomycin infusion. Cancer 44:19–25PubMedCrossRef

28.

De Andres L, Brunet J, Lopez-Pousa A et al (1995) Randomised trial of neoadjuvant cisplatin and flurouracil versus carboplatin and flurouracil in patients with stage IV-Mo head and neck cancer. J Clin Oncol 13:1493–1500PubMed

29.

Domenge C, Hill C, Lefebvre JL et al (2000) Randomised trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Grouoe d’Etude des Tumeurs de la tete et du Cou (GETTEC). Br J Cancer 83:1594–1598PubMedCrossRef

30.

(1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The department of veterans affairs laryngeal cancer study group. N Engl J Med 324:1685–1690

31.

Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of European Organisation for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899PubMedCrossRef

32.

Forastiere AA, Goepfert H et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRef

33.

Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159PubMedCrossRef

34.

Blanchard P, Baujat B, Holostenco V et al (2011) Meta-analysis of Chemotherapy in Head and Neck cancer (MACH-NC). A comprehensive analysis by tumour site. Radiother Oncol 100:33–40PubMedCrossRef

35.

Cooper JS, Pajak TF, Forastiere AA et al (2004) Post operative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of head and neck. N Engl J Med 350:1937–1944PubMedCrossRef

36.

Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952PubMedCrossRef

37.

Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N Engl J Med 354:567–578PubMedCrossRef

38.

Herbst RS, Arquette M, Shin DM et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck cancer. J Clin Oncol 23:5578–5587PubMedCrossRef

39.

Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646PubMedCrossRef

40.

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127PubMedCrossRef

41.

Babu KG, Viswanath L, Reddy BK et al (2010) An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J Clin Oncol 28:15s, suppl; abstr 5530

42.

Hong WK, Lippman SM, Itri LM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of head and neck. N Engl J Med 323:795–801PubMedCrossRef

43.

Argiris A, Karamouzis MV, Gooding WE et al (2010) Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer: Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4–8

44.

Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A et al (2007) Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 117:1173–1179PubMedCrossRef

Title: Systemic Therapy in Head and Neck Cancer: Changing Paradigm
Authors: Samit Purohit
Rohan Bhise
D. Lokanatha
K. Govindbabu
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Indian Journal of Surgical Oncology / Issue 1/2013
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-012-0197-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systemic Therapy in Head and Neck Cancer: Changing Paradigm

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Management of Recurrent Dermatofibro Sarcoma Protuberance of Scalp-a Reconstructive Challenge

Primary Denovo Squamous Cell Carcinoma Breast Masquerading as Breast Abscess

The Development of Supportive Care for Cancer Patients in India: A UK Perspective

Unresolving / Progressive Skin Lesions in Cancer Patients: Be Aware of Carcinoma Cutis

Primary Malignant Cystic Solitary Fibrous Tumour of the Spleen

Factors associated with better survival after surgery in metastatic breast cancer patients